Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,949.58 -945.25 (-1.46%) CMC Crypto 200
1,331.08 -65.46 (-4.69%)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
| Previous close | 899.41 |
| Open | 882.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 875.30 - 890.91 |
| 52-week range | 689.00 - 998.57 |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 984.616M |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | 70.31 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksEXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
ZacksRegeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
